U.S. Markets close in 3 hrs 44 mins
Stocks To Watch

Target soars on sales rebound, Urban Outfitters surges on beat, Apple eyes Hollywood

Enanta Pharmaceuticals, Inc. (ENTA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
39.800+0.170 (+0.429%)
As of 12:06PM EDT. Market open.
People also watch
EPZMFPRXXLRNMGNXOMED

Enanta Pharmaceuticals, Inc.

500 Arsenal Street
Watertown, MA 02472
United States
617-607-0800
http://www.enanta.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees76

Key Executives

NameTitlePayExercisedAge
Dr. Jay R. Luly Ph.D.Chief Exec. Officer, Pres & Director867.84kN/A61
Mr. Paul J. Mellett Jr.Sr. VP-Fin. & Admin. and CFO513.18kN/A62
Dr. Yat Sun Or Ph.D.Sr. VP-R&D and Chief Scientific Officer564.64kN/A65
Mr. Nathaniel S. Gardiner J.D.Sr. VP, Gen. Counsel & Sec.N/AN/A63
Dr. Timothy D. Ocain Ph.D.Sr. VP of New Product Strategy & Devel.N/AN/A59
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company’s research and development focuses on four disease targets: Hepatitis C virus (HCV), Hepatitis B virus (HBV), Non-alcoholic Steatohepatitis (NASH), and Respiratory Syncytial Virus (RSV). Its lead product is paritaprevir, a protease inhibitor designed for use against HCV. The company also develops HCV protease inhibitor in phase III development with AbbVie, as well as a HCV program using a different class of molecules known as cyclophilin inhibitors. In addition, it has a program in non-alcoholic steatohepatitis; and discovers programs in other areas of viral infection and liver disease. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with AbbVie to develop and commercialize HCV NS3 and NS3/4A protease inhibitors. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

Corporate Governance

Enanta Pharmaceuticals, Inc.’s ISS Governance QualityScore as of August 1, 2017 is 7. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 8; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.